Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II–IV
- 379 Downloads
Glioma is the most common intracranial primary brain tumor. Patients with glioma often suffer from epilepsy, anxiety and depression. Aims of this study were to identify risk factors for drug-treated anxiety and depression, and to determine the use of psychiatric medication in a national glioma cohort.
Data from the Cancer Registry of Norway on all persons diagnosed with glioma WHO grade II–IV 2004–2010 were linked with data from the Norwegian Prescription Database. Cox regression analysis was used to assess risk factors for drug-treated anxiety and depression. Standardized incidence ratios were calculated for psychiatric medication dispensed to glioma patients and compared to the general population.
The glioma cohort consisted of 1056 males and 772 females. Of the 1828 patients, 565 had glioma grade II–III, and 1263 had grade IV. The patients with glioma grade II–III who were treated with levetiracetam had an increased risk for drug-treated anxiety compared to patients without levetiracetam; hazard ratio 2.8 (95% confidence interval 1.7–4.9). Female gender increased the risk for drug-treated anxiety compared to males in patients with glioma grade IV; hazard ratio 1.5 (95% confidence interval 1.2–2.0). Antidepressants were less frequently dispensed to patients with glioma grade II–III and epilepsy than to the general population.
Patients with glioma grade II–III on levetiracetam had an increased risk for drug-treated anxiety. The subgroup of patients with glioma grade II–III and epilepsy received less antidepressants than the general population.
KeywordsAntiepileptic drugs Anxiety Depression Epilepsy Glioma
Funding was provided by University of Bergen (PhD scholarship).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The Regional Committee for Medical Research Ethics (REC West), reference 2011-02280, approved all aspects of this study.
- 1.Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology Task Force on G (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329 https://doi.org/10.1016/S1470-2045(17)30194-8 CrossRefGoogle Scholar
- 2.Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE (2014) Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 32:774–782. https://doi.org/10.1200/JCO.2013.51.8886 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological S (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133. https://doi.org/10.1111/j.1468-1331.2010.03151.x CrossRefPubMedGoogle Scholar
- 7.Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961–967. https://doi.org/10.1093/neuonc/not057 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
- 17.Aalen OO, Johansen S (1978) An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 5:141–150Google Scholar
- 18.Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Norgard BM, Guldberg R, Gradel KO (2017) Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol 135:571–579. https://doi.org/10.1007/s11060-017-2607-5 CrossRefPubMedGoogle Scholar
- 21.Bedetti C, Romoli M, Maschio M, Di Bonaventura C, Nardi Cesarini E, Eusebi P, Siliquini S, Dispenza S, Calabresi P, Costa C (2017) Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. Eur J Neurol 24:1283–1289. https://doi.org/10.1111/ene.13375 CrossRefPubMedGoogle Scholar
- 22.Belcastro V, Pisani LR, Bellocchi S, Casiraghi P, Gorgone G, Mula M, Pisani F (2017) Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. J Neurol 264:921–927. https://doi.org/10.1007/s00415-017-8463-6 CrossRefPubMedGoogle Scholar
- 31.Truven Health Analytics Inc (2018) https://www.mayoclinic.org/drugs-supplements/temozolomide-oral-route/side-effects/drg-20066228. Accessed 28 May 2018
- 36.Moreale R, Campanella F, Marin F, Skrap M, Palese A (2017) Emotional concerns and coping strategies in low grade glioma patients and reliability of their caregivers in reporting these concerns: Findings from a cross-sectional study. Eur J Oncol Nurs 30:113–119. https://doi.org/10.1016/j.ejon.2017.08.010 CrossRefPubMedGoogle Scholar
- 41.Arnold SD, Forman LM, Brigidi BD, Carter KE, Schweitzer HA, Quinn HE, Guill AB, Herndon JE 2nd, Raynor RH (2008) Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro Oncol 10:171–181. https://doi.org/10.1215/15228517-2007-057 CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, Kanner AM, Caplan R, Plioplys S, Salpekar J, Dunn D, Austin J, Jones J, Advisory Group of the Epilepsy Foundation as part of its Mood D (2008) Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 13(Suppl 1):S1–S29. https://doi.org/10.1016/j.yebeh.2008.04.005 CrossRefPubMedGoogle Scholar
- 48.Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A, Maguire P, House A, Ramirez A, Cull A (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 90:314–320. https://doi.org/10.1038/sj.bjc.6601578 CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Hendrix P, Hans E, Griessenauer CJ, Simgen A, Oertel J, Karbach J (2017) Neurocognitive status in patients with newly-diagnosed brain tumors in good neurological condition: the impact of tumor type, volume, and location. Clin Neurol Neurosurg 156:55–62. https://doi.org/10.1016/j.clineuro.2017.03.009 CrossRefPubMedGoogle Scholar